Antisense oligonucleotide for inducing expression enhancement by targeting UBE3a, and use thereof
Antisense oligonucleotides targeting the UBE3A gene pre-mRNA are used to enhance UBE3A expression by avoiding translation inhibitory sites, addressing the limitations of current Angelman Syndrome treatments and improving symptomatology.
Patent Information
- Application Number
- PCT/KR2024/017580
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-11-08
- Filing Date
- 2024-11-08
- Publication Date
- 2025-05-15
AI Technical Summary
Current treatments for Angelman Syndrome, caused by low levels or activity of functional UBE3A, are limited in efficacy and safety, necessitating the development of more effective therapeutic agents.
The use of antisense oligonucleotides (ASOs) that target the pre-mRNA of the human UBE3A gene, specifically designed to induce splicing and increase the expression of UBE3A by avoiding translation inhibitory sites in the mRNA.
The antisense oligonucleotides effectively increase the expression of UBE3A, improving symptoms associated with low UBE3A levels, such as those seen in Angelman Syndrome, while offering a safer and more effective treatment option.
Smart Images

Figure KR2024017580_15052025_PF_FP_ABST
Abstract
Description
Antisense oligonucleotide targeting UBE3A and inducing expression enhancement and use thereof
[0001] Disclosed are an antisense oligonucleotide targeting the pre-mRNA of the human UBE3A gene, which induces increased expression of UBE3A (Ubiquitin protein ligase E3A), and its use in treating diseases associated with functional UBE3A deficiency. The antisense oligonucleotide induces splicing to increase the production of mRNA of a productive isoform of UBE3A that does not contain a site that inhibits translation, thereby increasing the expression level of UBE3A, thereby treating or ameliorating diseases or symptoms caused by functional UBE3A deficiency in a subject.
[0002]
[0003] This research was supported by the Samsung Future Technology Promotion Project (Project Number: SRFC-MA2102-04).
[0004] Oligonucleotides are actively being used for the diagnosis and treatment of diseases. Unlike most biopharmaceuticals that target proteins, oligonucleotides target genes underlying disease, making them potentially useful for rare genetic diseases previously incurable, or for protein targets not effectively treated with small-molecule or protein therapeutics. Oligonucleotide-based therapeutics, in particular, offer the advantage of being significantly simpler to design and develop than small-molecule drugs and large-molecule biopharmaceuticals.
[0005] Antisense oligonucleotides (ASOs) bind to pre-mRNA or mRNA with a complementary sequence, modulating the splicing of pre-mRNA to create new proteins or inducing mRNA degradation to block protein production. Splicing regulation can suppress unwanted protein expression while increasing the expression of desired proteins or leading to the expression of new proteins. Therapeutics are exploiting these properties of RNA to develop therapeutics, and Exondys51, which induces exon skipping, has been approved by the US FDA for the treatment of Duchenne muscular dystrophy (DMD). mRNA can theoretically encode and produce any type of protein, while ASOs, which target RNA, have the advantage of enabling the development of therapeutics for proteins previously unavailable because the target site for inhibition is not exposed.
[0006] UBE3A, a ubiquitin protein ligase E3A, is an enzyme that targets proteins for degradation within cells. This enzyme attaches ubiquitin to proteins to be degraded, and the proteasome recognizes and degrades the ubiquitin-labeled proteins. This protein degradation process removes damaged or unnecessary proteins, maintaining normal cellular function. UBE3A plays a crucial role in the development and function of the nervous system, and loss of UBE3A gene function in the brain is known to cause the symptoms of Angelman syndrome, a genetic disorder that primarily affects the nervous system. While various antisense oligonucleotides targeting UBE3A are being developed as treatments for Angelman syndrome (e.g., U.S. Patent No. 1,132,0421, U.S. Patent No. 1,126,1446), there is a need for therapeutics that enhance UBE3A expression, either by being safer and more effective or by operating independently of other drugs to maximize therapeutic efficacy through combination therapy.
[0007] The present inventors identified a target region in the pre-mRNA of UBE3A that can induce enhanced expression of UBE3A, and developed an antisense oligonucleotide against it.
[0008]
[0009] The purpose is to provide an antisense oligonucleotide targeting the pre-mRNA of the UBE3A gene, which induces increased expression of UBE3A.
[0010] In addition, it is an object to provide a method for treating a disease associated with abnormal levels and / or activity of UBE3A using an antisense oligonucleotide targeting UBE3A pre-mRNA.
[0011] In addition, it is an object of the present invention to provide a method for screening genes having translation repressors or translation promoters regulated through alternative splicing.
[0012]
[0013] One aspect of the present invention is an antisense oligonucleotide targeting pre-mRNA of the human UBE3A gene,
[0014] The antisense oligonucleotide comprises 13 to 40 consecutive nucleotides and binds to the target site of UBE3A pre-mRNA through hybridization by at least 13 consecutive Watson-Crick base pairing A:T or G:C or wobble base pairing G:U, I:A, I:C or I:U, thereby increasing the expression of UBE3A.
[0015] The above target region provides an antisense oligonucleotide comprising a sequence selected from the group consisting of SEQ ID NOs: 9 to 11 and 47 to 66.
[0016] The target site of the antisense oligonucleotide that induces increased expression of the UBE3A gene was identified by exploring the region of the UBE3A pre-mRNA that influences the translational activity of the UBE3A mRNA. Specifically, through polysome profiling of cells, it was confirmed that the number of ribosomes bound per mRNA and consequently the translational activity of UBE3A differ depending on whether the two exons (e1, e2) within the 5'-UTR, or the intron region connecting these two exons, are included in the mature mRNA. Exons e1 and e2 within the 5'-UTR correspond to the sequences in the minus strand direction of chr15:25,408,620-25,408,684 and chr15:25,407,067-25,407,262, respectively, based on hg38. The presence of each exon e1 and e2 is interdependently related, such that the mRNA is spliced to include both e1 and e2 or to exclude both of them, and mRNA isoforms containing both e1 and e2, or e1, e2, and the intronic region connecting e1 and e2, have significantly lower translational activity than mRNA isoforms that do not contain them, confirming that they act as translational repression sites. The target site, which includes exons e1, e2 and the intron region connecting e1 and e2, which were identified as translational repression sites, was the 5'-UTR region of the pre-mRNA of UBE3A, the minus strand of chr15:25,407,067-25,408,684 (hg38) (SEQ ID NO: 97), exon e1 was the minus strand of chr15:25,408,620-25,408,684 (hg38) (SEQ ID NO: 98), and exon e2 was the minus strand of chr15:25,407,067-25,407,262 (hg38) (SEQ ID NO: 99).Antisense oligonucleotides targeting sequences selected from the group consisting of SEQ ID NOs: 1 to 21 within the 5'-UTR target region were designed and confirmed to induce splicing such that the translational repression site in the pre-mRNA is not incorporated into the mature mRNA, thereby increasing the mRNA of the productive isoform and thereby increasing the expression of UBE3A. Antisense oligonucleotides targeting sequences of SEQ ID NOs: 47 to 66 within the target region were additionally designed, focusing on the target region of the antisense oligonucleotides confirmed to have high activity in increasing the production of the mRNA of the productive isoform and increasing the expression of UBE3A, and these were screened for increasing the expression of UBE3A.
[0017] In one embodiment of the present invention, the antisense oligonucleotide comprises a contiguous sequence that is at least 80% complementary to a target region of a sequence selected from the group consisting of SEQ ID NOs: 11, 51, 62, and 63, for example, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or 100% complementary.
[0018] In one specific embodiment of the present invention, the antisense oligonucleotide may have a length of, but is not limited to, 14 to 30, 15 to 25, 17 to 24, or 18 to 20 nucleotides.
[0019] In one embodiment of the present invention, the antisense oligonucleotide is completely complementary (100% complementary) to a target region of a sequence selected from the group consisting of SEQ ID NOs: 9 to 11 and 47 to 66, or may contain a mismatch, for example, one, two, three or more consecutive mismatches, sufficient to bind to the target region through hybridization by at least 13 consecutive Watson-Crick base pairs or floating base pairs to increase the expression of UBE3A.
[0020] In one embodiment of the present invention, the target site may comprise a sequence selected from the group consisting of SEQ ID NOs: 11, 51, 62, and 63.
[0021] In one specific embodiment of the present invention, the target site may comprise a sequence selected from the group consisting of SEQ ID NOs: 11 and 63.
[0022]
[0023] One aspect of the present invention is an antisense oligonucleotide targeting pre-mRNA of the human UBE3A gene,
[0024] The antisense oligonucleotide comprises 13 to 40 consecutive nucleotides and binds to more than 80% of the nucleobases of the target sequence of UBE3A pre-mRNA through hybridization by Watson-Crick base pairing A:T or G:C or floating base pairing G:U, I:A, I:C or I:U, thereby increasing the expression of UBE3A.
[0025] The above target sequence provides an antisense oligonucleotide having a sequence selected from the group consisting of SEQ ID NOs: 9 to 11 and 47 to 66.
[0026] In one specific embodiment of the present invention, the antisense oligonucleotide may be a sequence selected from the group consisting of SEQ ID NOs: 11, 51, 62, and 63.
[0027] In one specific embodiment of the present invention, the antisense oligonucleotide may be a sequence selected from the group consisting of SEQ ID NOs: 11 and 63.
[0028] In one specific embodiment of the present invention, the antisense oligonucleotide can increase the expression of UBE3A by binding to at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, or at least 99% of the nucleobases of the target sequence of UBE3A pre-mRNA through hybridization via Watson-Crick base pairs A:T or G:C or floating base pairs G:U, I:A, I:C, or I:U.
[0029]
[0030] As used herein, the term "antisense oligonucleotide" refers to a nucleic acid sequence complementary to a target DNA or mRNA sequence, and is used interchangeably herein with "antisense oligomer" or "ASO." Antisense oligonucleotides are generally designed to bind to a target and increase expression of the RNA target by modulating its expression or activity at the transcription, translation, or splicing levels. Antisense oligonucleotides are designed to hybridize to a gene, such as UBE3A or its transcript, under cellular conditions. Thus, the oligonucleotide is designed to be sufficiently complementary to its target, i.e., to hybridize with sufficient specificity to produce the desired effect in a cellular environment.
[0031] The term "5'-untranslated region (5'-UTR)" as used herein refers to a region of an mRNA that is important in regulating the translation of the transcript. The 5'-UTR begins at the transcription initiation site and ends at the nucleotide preceding the initiation sequence of the coding region (typically, AUG).
[0032] As used herein, the term "target site of pre-mRNA of the UBE3A gene" or "target site of UBE3A pre-mRNA" refers to a site in UBE3A pre-mRNA that is targeted by an oligonucleotide to induce enhanced expression of UBE3A. This may be exon e1, e2, a portion thereof, or a surrounding region that acts as a translational repression site, and an antisense oligonucleotide designed thereto can act to induce splicing so that e1 and e2 are not included in the mRNA.
[0033] The term "UBE3A" used herein refers to ubiquitin protein ligase E3A. Ubiquitin protein ligase is an enzyme that attaches ubiquitin to proteins to be degraded, and the proteasome recognizes and degrades ubiquitin-tagged proteins. Protein degradation is a process that removes damaged or unnecessary proteins and maintains normal cellular function. UBE3A plays a crucial role in the development and function of the nervous system, contributing to the regulation of the balance between protein synthesis and degradation at the synapses between nerve cells where cell-to-cell communication occurs. Loss of UBE3A gene function in the brain causes many of the unique features of Angelman syndrome, a complex genetic disorder primarily affecting the nervous system. Genetic mutations or abnormalities that result in the inactivation or deletion of the UBE3A gene, resulting in a deficiency or lack of functional UBE3A, can result in Angelman syndrome.
[0034] As used herein, the term "splicing" refers to the process by which pre-mRNA transcribed from DNA is converted into mature mRNA, in which introns are removed and exons are joined. "Alternative splicing" refers to the generation of mRNA with different structures or compositions, i.e., mRNA isoforms, depending on which introns or exons are removed or retained from a single pre-mRNA.
[0035] The term "exon" as used herein means a portion of a gene that encodes a portion of the final mature RNA from which introns have been removed by RNA splicing, and refers to the DNA sequence of the gene and the corresponding sequence in the RNA transcript.
[0036] The term "intron" as used herein refers to a nucleotide sequence within a gene that is removed by RNA splicing during maturation of the final RNA product, and refers to the corresponding sequence in the DNA sequence of the gene and the RNA transcript.
[0037] The term "exon skipping" or "exon skipping" as used herein means that splicing of a pre-mRNA results in the generation of an mRNA lacking the exon, for example, when an antisense oligonucleotide targeting the exon binds, thereby inhibiting the formation of the spliceosome complex that mediates splicing, resulting in the generation of an mRNA that does not include the exon.
[0038] As used herein, the term "productive isoform" refers to an isoform of the final mRNA obtained by splicing of pre-mRNA that does not contain an exon that acts as a translational repression site, and which can be translated with a higher translational activity than in the presence of the translational repression site. The term "unproductive isoform" refers to an isoform of the mRNA obtained by splicing of pre-mRNA that contains a translational repression site, and which cannot be translated into the final product, or which can be translated with a low yield due to translational repression, or which can be translated into the final product with impaired or compromised function.
[0039] As used herein, the term "translational inhibition site" refers to a site or region consisting of one or more bases on a pre-mRNA, which, when included in the final mature mRNA, results in lower translational activity compared to when not included. The translational inhibition site may be an exon. The term "translational inhibition site" is used interchangeably herein with "translational inhibition element" and "translational inhibition factor."
[0040] The term "translational activity" as used herein refers to the activity of mRNA translating into protein, and can be measured by the amount or level of protein, or the number of ribosomes bound per mRNA. The greater the number of ribosomes bound per mRNA for translation, the higher the translational activity. The fewer the number of ribosomes bound per mRNA, the lower the translational activity. Translational activity can be analyzed by polysome profiling.
[0041] As used herein, the term "complementarity" refers to the ability of a nucleoside / nucleotide to form Watson-Crick base pairs. Watson-Crick base pairs are guanine (G)-cytosine (C) and adenine (A)-thymine (T) / uracil (U). Oligonucleotides may include nucleosides with modified nucleobases, for example, 5-methylcytosine is often used in place of cytosine, and thus complementarity includes Watson-Crick base pairing between an unmodified nucleobase and a modified nucleobase.
[0042] As used herein, the term "Watson-Crick base pair" means a base pair between A and T (A:T) or between C and G (G:C), and "floating base pair" means a base pair between G and U (G:U), I and A (I:A), I and C (I:C), or I and U (I:U).
[0043] The term "% complementarity" as used herein refers to the proportion of complementary nucleotides capable of forming base pairs between nucleic acid molecules. % complementarity is calculated by counting the number of aligned bases that form pairs between two sequences, dividing by the total number of nucleotides in the oligonucleotide, and multiplying by 100. Nucleobases / nucleotides that do not align, i.e., do not form base pairs, in a comparison of two sequences are referred to as mismatches. An antisense oligonucleotide can be at least 80% complementary to a target site, for example, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% complementary. An antisense oligonucleotide may contain one, two, or three base mismatches relative to the target site, or may contain more than one base mismatch, as long as it has sufficient complementarity to effectively bind to the target site.
[0044] The term "homology," as used herein, refers to the percentage of amino acid sequences, or in the case of bases, that are identical at a particular position between polymers such as compared polypeptides or polynucleotides, and may be used interchangeably with "identity" for sequences. Two sequences may be considered "homologous" if they are at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identical. For example, the percent homology of two polynucleotide sequences can be calculated by aligning the two sequences for optimal comparison purposes, comparing the nucleotides at corresponding nucleotide positions, and determining that if a position in the first sequence has the same nucleotide as the corresponding position in the second sequence, the two sequences are considered identical at that position. Sequence homology can be determined using software such as BLASTP, BLASTN, and FASTA.
[0045] In one specific embodiment of the present invention, the antisense oligonucleotide may bind to a target site of UBE3A pre-mRNA, thereby inducing splicing to produce a productive isoform of UBE3A mRNA that does not contain a site that inhibits translation of UBE3A, thereby increasing the expression of UBE3A.
[0046] We confirmed that splicing of two exons (e1, e2), which were identified by polysome profiling as causing low translational activity, to prevent their inclusion in mRNA increased the production of the productive isoform mRNA, thereby increasing the expression of the UBE3A protein. The exons that cause low translational activity when present act as translational repression sites, and conjugating antisense oligonucleotides to these sites to induce splicing so that they are not included increased the production of the productive isoform.
[0047] An antisense oligonucleotide does not necessarily require 100% sequence complementarity to bind (hybridize) to the target site and exert its intended effect. Since binding of the antisense oligonucleotide to the target site can result in the production of mRNA of a productive isoform if the antisense oligonucleotide binds to the target site and forms a complex that prevents splicing of the target site into mRNA, the antisense oligonucleotide and the target site only need to be complementary enough to induce mRNA of the productive isoform. For example, the antisense oligonucleotide and the target site can be complementary at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or at least 100%.
[0048] In some embodiments, the antisense oligonucleotide may contain a mismatch to the target site nucleic acid of the UBE3A 5'-UTR. Despite the mismatches, hybridization of the antisense oligonucleotide to the target site may still be sufficient to induce alternative splicing, resulting in increased UBE3A expression. The decreased binding affinity resulting from the mismatches may advantageously be compensated for by an increased number of nucleotides within the oligonucleotide and / or an increased number of modified nucleosides, such as 2'-modified nucleosides, including LNAs, present within the oligonucleotide sequence that can increase binding affinity for the target.
[0049] In one embodiment of the present invention, the antisense oligonucleotide may comprise or consist of a sequence selected from the group consisting of SEQ ID NOs: 29, 31, 33 to 35, 37, and 39 to 44, or a sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, or at least 99% homology thereto.
[0050] The antisense oligonucleotide is designed to have complementarity to the target site and to induce splicing to increase the production of a productive isoform mRNA, and is selected by confirming its activity. Since the intended effect is achieved when the antisense oligonucleotide can bind to the target site or an adjacent site including the target site and induce splicing such that the target site, i.e., the site having translational suppression activity, is not included in the mRNA, an antisense oligonucleotide or an antisense oligonucleotide having 80% or more homology thereto, for example, 85% or more, 90% or more, 95% or more, 98% or more, 99% or more, or 100% homology thereto, can be effective.
[0051] By designing multiple antisense oligonucleotides that bind to the same target site and adjacent sites thereof and confirming their effects on binding to the target site and consequent splicing, it was confirmed that an antisense oligonucleotide of a specific sequence and an antisense oligonucleotide having at least 80% sequence identity thereto have the same or similar effects.
[0052] In one specific embodiment of the present invention, the antisense oligonucleotide may comprise or consist of SEQ ID NO: 33 or 34, or a sequence having at least 80% homology thereto.
[0053] In one specific embodiment of the present invention, the antisense oligonucleotide may target a sequence selected from the group consisting of SEQ ID NOs: 47 to 66.
[0054] Antisense oligonucleotides comprising the sequence of SEQ ID NO: 33 or 34, for example, antisense oligonucleotides a405 and a406, showed excellent activity in increasing the expression of UBE3A by acting on the target site, and antisense oligonucleotide sequences targeting the target site and its surroundings were designed. SEQ ID NOs: 47 to 66 correspond to sequences of adjacent regions centered on the target site of SEQ ID NO: 33 or 34. It was confirmed that all antisense oligonucleotides additionally designed for the target site of the antisense oligonucleotides that were confirmed to have a high effect in increasing the production of productive isoforms effectively induce enhanced expression of UBE3A by reducing the production of non-productive isoforms and increasing the production of productive isoforms. The activity by these additionally designed antisense oligonucleotides demonstrates that not only antisense oligonucleotides having 100% homology to the target site, but also antisense oligonucleotides having sufficient complementarity to have the intended antisense oligonucleotide activity, for example, having at least 80% complementarity, or sequences having at least 80% homology to antisense oligonucleotides having activity, function effectively as antisense oligonucleotides.
[0055] In one specific embodiment of the present invention, the antisense oligonucleotide may comprise or consist of a sequence selected from the group consisting of SEQ ID NOs: 67 to 86, or a sequence having at least 80% homology thereto.
[0056] In one specific embodiment of the present invention, the antisense oligonucleotide may comprise or consist of a sequence selected from the group consisting of SEQ ID NOs: 71, 75, 82, and 83, or a sequence having at least 80% homology thereto.
[0057] In one embodiment of the present invention, the antisense oligonucleotide may comprise one or more modifications of a chemically modified sugar moiety, a chemically modified base, and a chemically modified internucleoside linkage.
[0058] In one specific embodiment of the present invention, the chemically modified sugar moiety may be selected from a sugar moiety modified with 2'-O-methyl, 2'-methoxyethoxy, 2'-OAmethoxyethyl (2'-MOE), 2'-dimethylaminoethoxy, 2'-dimethylaminoethoxyethoxy, 2'-fluoro, 2'-acetamide, morpholino, LNA (locked nucleic acid), and c-ET (S-contrained-ethyl).
[0059] The modified base may be selected from the group consisting of isocytosine, pseudoisocytosine, 5-methyl-cytosine, 5-fluorocytosine, 5-thiozolo-cytosine, 5-propynyl-cytosine, 5-propynyl-uracil, 5-bromouracil, 5-thiazolo-uracil, 2-thio-uracil, 2'thio-thymine, inosine, diaminopurine, 6-aminopurine, 2-aminopurine, 2,6-diaminopurine and 2-chloro-6-aminopurine, and / or
[0060] The chemically modified internucleoside linkage may be a phosphorothioate linkage or a phosphorodiamidate linkage.
[0061] In one embodiment of the present invention, the antisense oligonucleotide comprises one or more modifications of a chemically modified sugar moiety, a chemically modified base, and a chemically modified internucleoside linkage,
[0062] The chemically modified sugar moiety comprises at least one of a sugar moiety modified with 2'-O-methyl, 2'-methoxyethoxy, 2'-OAmethoxyethyl (2'-MOE), 2'-dimethylaminoethoxy, 2'-dimethylaminoethoxyethoxy, 2'-fluoro, 2'-acetamide, morpholino, LNA (locked nucleic acid), or c-ET (S-contrained-ethyl),
[0063] The modified base comprises at least one of 5-methyl-cytosine, 5-fluorocytosine, and 2-aminopurine bases,
[0064] The chemically modified internucleoside linkage may include a phosphorothioate linkage.
[0065] In one specific embodiment of the present invention, the antisense oligonucleotide may be composed of a nucleoside having a 2'-MOE modification, wherein the internucleoside linkages are phosphorothioates, and all cytosine (C) bases are 5'-methyl-cytosines.
[0066] In one embodiment of the present invention, the antisense oligonucleotide is composed of a nucleoside having a 2'-MOE modification, wherein the internucleoside linkages are phosphorothioates, and all cytosine (C) bases may be 5'-methyl-cytosines.
[0067] In one embodiment of the present invention, the antisense oligonucleotide comprises or consists of the sequence of SEQ ID NO: 33, 34, 70, 82 or 83, wherein all nucleotides are nucleosides having a 2'-MOE modification, the internucleoside linkages are phosphorothioates, and all cytosine (C) bases can be 5'-methyl-cytosines.
[0068] In one specific embodiment of the present invention, the antisense oligonucleotide has one of the structures of the following chemical formulas (I) to (IV):
[0069] A*A*G*A*T*T*G*C*T*T*C*C*A*A*A*C*T*T*G*T Formula (I);
[0070] A*T*T*G*C*T*T*C*C*A*A*A*C*T*T*G*T*A*T*C*T Formula (II);
[0071] C*C*C*C*A*A*G*A*T*T*G*C*T*T*C*C*A*A*A*C Formula (III); and
[0072] G*T*A*C*C*C*A*A*G*A*T*T*G*C*T*T*C*C Formula (IV);
[0073] In the formula, A can be 2'MOE-A, C can be 2'MOE-5'-methyl-C, G can be 2'MOE-G, T can be 2'MOE-T, * can be PS (phosphorothioate), and 2'MOE can be 2'-O-methoxyethyl.
[0074] In one specific embodiment of the present invention, the antisense oligonucleotide has one of the structures of the following chemical formulas (I) and (IV):
[0075] A*A*G*A*T*T*G*C*T*T*C*C*A*A*A*C*T*T*G*T Formula (I); and
[0076] G*T*A*C*C*C*A*A*G*A*T*T*G*C*T*T*C*C Formula (IV);
[0077] In the formula, A can be 2'MOE-A, C can be 2'MOE-5'-methyl-C, G can be 2'MOE-G, T can be 2'MOE-T, * can be PS (phosphorothioate), and 2'MOE can be 2'-O-methoxyethyl.
[0078]
[0079] The term "modified oligonucleotide" as used herein means an oligonucleotide comprising one or more sugar-modified nucleosides and / or modified internucleoside linkages.
[0080] The term "chemical modification" as used herein means introducing chemically modified nucleosides or internucleoside linkages into an antisense oligonucleotide to increase the nucleobase sequence of the antisense oligonucleotide, such as nuclease resistance and / or binding affinity for a target nucleic acid.
[0081] The term "modified nucleoside" as used herein means a nucleoside which is modified compared to an equivalent DNA or RNA nucleoside by introduction of one or more modifications of the sugar moiety or the (nucleo)base moiety.
[0082] As used herein, the term "internucleoside linkage" or "internucleoside linkage" refers to a bond or linkage that covalently links two nucleosides to each other, including but not limited to a phosphodiester (PO) linkage. In natural oligonucleotides, the internucleoside linkage comprises phosphate groups that create a phosphodiester linkage between adjacent nucleosides. Modified internucleoside linkages increase the nuclease resistance of the oligonucleotide compared to phosphodiester linkages. Modified internucleoside linkages are particularly useful for stabilizing oligonucleotides for in vivo use. Modified internucleoside linkages or linkages include but are not limited to a phosphorothioate linkage or a phosphorodiamidate linkage.
[0083] As used herein, the term "nucleobase" includes purine (e.g., adenine and guanine) and pyrimidine (e.g., uracil, thymine, and cytosine) residues present in nucleosides and nucleotides that form hydrogen bonds during nucleic acid hybridization. As used herein, the term "nucleobase" also encompasses modified nucleobases that may differ from naturally occurring nucleobases but are functional during nucleic acid hybridization. In this context, "nucleobase" encompasses both naturally occurring nucleobases such as adenine, guanine, cytosine, thymidine, uracil, xanthine, and hypoxanthine, as well as non-naturally occurring variants.
[0084]
[0085] Another aspect of the present invention provides a pharmaceutical composition for the treatment of a disease associated with abnormal levels and / or activity of UBE3A, comprising the antisense oligonucleotide described above.
[0086] In one specific embodiment of the present invention, the disease may be Angelman syndrome.
[0087]
[0088] Another aspect of the present invention provides a pharmaceutical composition for treating a disease in which a therapeutic effect is confirmed through enhanced expression of UBE3A, comprising a virus that expresses the aforementioned antisense oligonucleotide in a cell.
[0089] In one specific embodiment of the present invention, the disease may be Angelman syndrome.
[0090]
[0091] In one specific embodiment of the present invention, the antisense oligonucleotide has one of the structures of the following chemical formulas (I) to (IV):
[0092] A*A*G*A*T*T*G*C*T*T*C*C*A*A*A*C*T*T*G*T Formula (I);
[0093] A*T*T*G*C*T*T*C*C*A*A*A*C*T*T*G*T*A*T*C*T Formula (II);
[0094] C*C*C*C*A*A*G*A*T*T*G*C*T*T*C*C*A*A*A*C Formula (III); and
[0095] G*T*A*C*C*C*A*A*G*A*T*T*G*C*T*T*C*C Formula (IV);
[0096] In the formula, A can be 2'MOE-A, C can be 2'MOE-5'-methyl-C, G can be 2'MOE-G, T can be 2'MOE-T, * can be PS (phosphorothioate), and 2'MOE can be 2'-O-methoxyethyl.
[0097] In one specific embodiment of the present invention, the antisense oligonucleotide may comprise a sequence selected from the group consisting of SEQ ID NOs: 29, 31, 33 to 35, 37, and 39 to 44, or a sequence having at least 80% homology thereto.
[0098] In one embodiment of the present invention, the antisense oligonucleotide comprises or consists of the sequence of SEQ ID NO: 33, 34, 70, 82 or 83, wherein all nucleotides are nucleosides having a 2'-MOE modification, the internucleoside linkages are phosphorothioates, and all cytosine (C) bases can be 5'-methyl-C.
[0099] In one specific embodiment of the present invention, the antisense oligonucleotide may be a combination of antisense oligonucleotides having different sequences.
[0100] In one specific embodiment of the present invention, the pharmaceutical composition may further include pharmaceutically acceptable excipients, additives, etc.
[0101] In one embodiment of the present invention, the pharmaceutical composition may further comprise another therapeutic agent for the treatment of a disease associated with abnormal levels and / or activity of UBE3A. The antisense oligonucleotide and the other therapeutic agent may be administered simultaneously or separately.
[0102]
[0103] The pharmaceutical composition according to the present invention is administered in a therapeutically effective amount, i.e., an amount capable of producing the desired therapeutic effect. The therapeutically effective amount is preferably an appropriate dose capable of treating a disease associated with abnormal levels and / or activity of UBE3A, and may be determined by taking into account certain factors, including the body weight, sex, age of the subject to be treated, the specific composition being administered, the active ingredient(s) in the composition, the time and route of administration, the general health, and other drugs being administered simultaneously. The pharmaceutical composition according to the present invention may be administered, for example, orally or parenterally, for example, by subcutaneous injection, intravenous injection or infusion, intraarterial injection or infusion, intramuscular injection, topical administration, or administration to a target organ. The antisense oligonucleotide according to the present invention can be administered intravenously or subcutaneously, and can be administered in a dose ranging from 0.1 mg / kg to 50 mg / kg, from 0.1 mg / kg to 30 mg / kg, from 0.1 mg / kg to 20 mg / kg, from 0.1 mg / kg to 5 mg / kg, or from 0.5 mg / kg to 5 mg / kg, but is not limited thereto.
[0104]
[0105] The term "Angelman syndrome" as used herein refers to a genetic disorder primarily affecting the nervous system that occurs when there is an abnormality in chromosome 15, which is inherited from the mother. It usually occurs when there is an issue with the UBE3A gene, resulting in insufficient or low levels or activity of functional UBE3A. Therefore, symptoms can be treated or improved by increasing the expression of UBE3A, thereby raising the levels and / or activity of UBE3A to normal levels.
[0106] The term "disease associated with abnormal levels or activity of UBE3A" as used herein means a disease caused by lower than normal or insufficient levels or activity of functional UBE3A, for example, Angelman syndrome.
[0107]
[0108] Another aspect of the present invention provides a method of treating a disease associated with an abnormal level or activity of UBE3A, comprising administering a therapeutically effective amount of the antisense oligonucleotide described above.
[0109] The term "therapeutically effective amount" as used herein means the amount of an active ingredient necessary to achieve the desired therapeutic effect, for example, the amount of an antisense oligonucleotide that can alleviate, relieve, improve or cure Angelman syndrome or its symptoms.
[0110] In specific embodiments of the present invention, the antisense oligonucleotides of the present invention can be administered by parenteral routes, including intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection or infusion, intrathecal or intracranial, for example, intracerebral or intracerebroventricular administration.
[0111]
[0112] Another aspect of the present invention is a method for screening a gene having a translation repressor or translation promoter regulated through alternative splicing,
[0113] A step of obtaining polysome profile data for human or animal cells,
[0114] A step of analyzing the above polysome profile data to select translation promoting factors and / or translation repressing factors regulated through alternative splicing,
[0115] The above selection step selects a region that increases the number of ribosomes bound to mRNA when present as a translation promoting factor,
[0116] A method is provided for selecting a site that reduces the number of ribosomes bound to mRNA when present as a translation repressor.
[0117]
[0118] The number of ribosomes bound to each mRNA can be analyzed through polysome profiling in samples obtained from cells, and the greater the number of ribosomes bound to each mRNA, the more active translation occurs, and therefore, it can be judged that the translation activity is high. Through polysome profiling, mRNA is isolated according to the number of ribosomes bound to each mRNA, and the mRNA of each isolated fraction is analyzed by RNA-seq to confirm the sequence, and by comparing the sequences of each fraction, the region that affects translation activity can be identified. For example, mRNA containing exons e1 and / or e2 present in the 5'-UTR of UBE3A pre-mRNA had low translation activity, whereas mRNA not containing exons e1 and e2 had high translation activity, and through this, exons e1 and e2 were identified as translation repressors.
[0119] In one specific embodiment of the present invention, the step of obtaining polysome profile data for the human or animal cell comprises:
[0120] A step of obtaining a lysate from a human or animal cell and fractionating the mRNA according to the number of ribosomes bound to the mRNA through a sucrose gradient, and
[0121] comprising a step of performing RNA-seq on each fraction of the isolated mRNA to generate polysome profile data identifying the mRNA present in each fraction, or
[0122] It may include a step of obtaining polysome profile data for the human or animal cells that have been performed.
[0123]
[0124] The term "translation accelerator" as used herein refers to a region in mRNA that, when present, enhances translation activity, and may be composed of one or more bases. If the presence of a specific region, i.e., a base or base sequence, increases the translation activity of the mRNA, and its removal decreases translation activity, it can be determined to function as a translation accelerator. An mRNA isoform that contains a translation accelerator is a productive isoform that results in the production of the desired end product, whereas an mRNA isoform that does not contain a translation accelerator and thus reduces the production of the end product through translation is a non-productive isoform. A translation accelerator may not be part of the end product.
[0125] The term "translation repressor" as used herein refers to a region in an mRNA that, when present, reduces translation activity, and may be composed of one or more bases. If the presence of a specific region, i.e., a base or base sequence, reduces the translation activity of the mRNA, and if the removal of the region increases the translation activity, it can be determined to act as a translation repressor. An mRNA isoform that does not contain a translation repressor is a productive isoform that results in the production of the desired end product, whereas an mRNA isoform that contains a translation repressor and reduces the production of the end product by translation is a non-productive isoform.
[0126] The term "polysome," as used herein, refers to a structure in which multiple ribosomes bind to mRNA for translation. The number of ribosomes bound per mRNA indicates translation activity. A higher number of ribosomes indicates higher translation activity. To determine translation activity in cell or organism samples, polysome profiles can be examined, from which the degree of translation activity and the sites or factors affecting translation activity can be identified.
[0127] In one embodiment of the present invention, the selected translation repressor or translation promoter can be used as a target of an antisense oligonucleotide that induces splicing to regulate the expression level of a target gene.
[0128] In one embodiment of the present invention, an antisense oligonucleotide can be designed to induce splicing to remove the translation repressor to increase expression of the target gene.
[0129] In one embodiment of the present invention, an antisense oligonucleotide that induces splicing can be designed to include the translation repressor to reduce the expression of the target gene.
[0130] In one embodiment of the present invention, an antisense oligonucleotide that induces splicing can be designed to include the translation promoting factor to increase the expression of the target gene.
[0131] In one embodiment of the present invention, an antisense oligonucleotide can be designed to induce splicing to exclude the translation promoting factor in order to reduce the expression of the target gene.
[0132]
[0133] An antisense oligonucleotide according to one embodiment of the present invention can increase the expression of UBE3A by increasing the productive isoform of UBE3A, and thus can be effectively used in the treatment of diseases associated with abnormal levels and / or activity of UBE3A, such as Angelman syndrome. In addition, a method for screening translational repressors and / or translational promoters based on a polysome profile according to one embodiment of the present invention can be useful in the design of target sites and oligonucleotides for regulating the expression of target genes.
[0134]
[0135] Figure 1 is a schematic diagram showing a strategy for increasing gene expression through ASO-mediated exon skipping of a 5'-untranslated region (5'-UTR) containing a translation inhibitory element according to one embodiment of the present invention. A indicates the location of the 5'-untranslated region (5'-UTR) present in messenger RNA (mRNA), and B represents a strategy for reducing the production of unproductive isoforms having exons containing translation inhibitory elements by selectively modulating splicing using an antisense oligonucleotide (ASO), while simultaneously increasing the production of productive isoforms that do not contain the exon, ultimately increasing the amount of protein expression.
[0136] Figure 2 shows the analysis of HEK293T polysome profile data for the discovery of a target region within the UBE3A5' untranslated region according to one specific example of the present invention. mRNAs present in HEK293T cells were separated according to the number of bound ribosomes (translation efficiency), and RNA-seq was performed on each separated fraction to obtain polysome profile data (GEO accession number: GSE69352). From this, it was confirmed that when two exons (e1, e2) present within the UBE3A5' untranslated region are spliced in the direction that includes them, translation efficiency is reduced, thereby identifying the presence of a translation repressor in the corresponding region.
[0137] FIG. 3 shows the analysis of human neuronal polysome profile data (GEO accession number: GSE100007) for the discovery of a target region within the UBE3A5' untranslated region according to one embodiment of the present invention. It was also confirmed in cultured human neural cells that the translation efficiency of the UBE3A gene is reduced when two exons (e1, e2) within the UBE3A5' untranslated region are included and spliced.
[0138] Figure 4 shows the results of measuring the ratio of productive and unproductive isoforms classified according to translation efficiency for the verification of the target region within the UBE3A5' untranslated region according to one specific example of the present invention. The unproductive isoform refers to an mRNA isoform that includes two exons with translation repression factors, resulting in low translation efficiency, and the productive isoform refers to an mRNA isoform that is spliced so that two exons with translation repression activity are excluded.
[0139] Figure 5 shows the expression level of the target region within the UBE3A5'untranslated region in each human tissue according to one specific example of the present invention.
[0140] Figure 6 shows a schematic diagram of an ASO strategy for a target region within the UBE3A5' untranslated region according to one specific example of the present invention.
[0141] Figure 7 shows the locations of 21 antisense oligonucleotides designed around exon e2, one of the target regions within the UBE3A5' untranslated region, according to one specific embodiment of the present invention. The sequence presented in Figure 7 corresponds to chr15:25,407,025-25,407,296 based on hg38, and is indicated in the direction of the minus strand. The region delineated by the rectangular box corresponds to exon e2, and the designed antisense oligonucleotides are indicated by arrow-shaped boxes.
[0142] Figures 8a and 8b illustrate the screening results of ASOs designed around exon e2, one of the target regions within the UBE3A5' untranslated region, and its surroundings, according to one specific embodiment of the present invention. Figure 8a shows the results of RT-PCR, and Figure 8b displays the ratio of non-productive isoforms to total isoforms from the RT-PCR results compared to a mock condition. The mock condition is a condition in which only lipofectamine LTX was treated without injecting ASOs.
[0143] Figure 9 shows the positions and sequences of primers for RT-PCR to confirm the relative expression levels of isoforms constituting the target region within the UBE3A5' untranslated region according to one specific example of the present invention.
[0144] Figure 10 illustrates the optimized design of an ASO for a target region within the UBE3A5' untranslated region according to one embodiment of the present invention. Twenty additional ASOs (shaded arrow-shaped boxes) were designed around a405 and a406 (arrow-shaped boxes), which showed the highest efficacy in the first screening. The sequence presented in Figure 10 corresponds to chr15:25,407,064-25,407,284 based on hg38 and is indicated in the direction of the minus strand. The e2 exon region (chr15:25,407,067-25,407,262, hg38, minus strand, 196 nt), which is the target exon of the designed ASO, is indicated by a rectangular box.
[0145] Figures 11a and 11b illustrate the screening results of an optimized ASO designed for a target region within the UBE3A5' untranslated region according to one embodiment of the present invention. Figure 11a shows the results of RT-PCR, and Figure 11b displays the ratio of non-productive isoforms to total isoforms from the RT-PCR results compared to a mock condition. The mock condition is a condition in which only lipofectamine LTX was treated without ASO injection.
[0146] Figures 12a and 12b show changes in UBE3A protein expression in K562 cells by ASO targeting a region within the UBE3A 5'untranslated region according to one embodiment of the present invention. Figure 12a shows the results of Western blot analysis, and Figure 12b shows the fold change compared to the condition without ASO treatment (Mock) after normalizing the UBE3A expression values in the results of Figure 12a to the b-actin and GAPDH expression values, respectively.
[0147] Figure 13 shows the results of analyzing the change in the expression of UBE3A mRNA isoform in K562 cell line by a406, an ASO according to one specific example of the present invention, using RNA-seq.
[0148] Figure 14 shows the results of RT-PCR evaluation of the similarity of UBE3A isoform expression between brain-like models (D160 cerebral organoids, K562 cell line, D40 human neuronal cells) and human brain tissues (human whole brain tissue, human cerebral cortex tissue) used in the ASO screening evaluation according to one specific example of the present invention.
[0149] Figure 15 shows the positions and sequences of primers and probes used in UBE3A isoform-specific RT-qPCR performed to evaluate the effect of ASO according to one embodiment of the present invention on changes in UBE3A isoform expression patterns.
[0150] Figures 16a and 16b show the dose-dependent effect of a406 according to one embodiment of the present invention on UBE3A splicing in human cerebral organoids (1 week). Figure 16a shows RT-PCR results, and Figure 16b shows UBE3A isoform-specific RT-qPCR results, where the expression levels of each UBE3A isoform relative to GAPDH mRNA are expressed as fold change compared to the condition without ASO treatment (Mock).
[0151] Figures 17a and 17b show the dose-dependent effect of a406 according to one embodiment of the present invention on UBE3A splicing in human cerebral organoids (2 weeks). Figure 17a shows the results of RT-PCR and qRT-PCR, and Figure 17b shows the results of UBE3A isoform-specific RT-qPCR, showing the expression levels of each UBE3A isoform relative to GAPDH mRNA as fold change compared to the condition without ASO treatment (Mock).
[0152] Figures 18a and 18b show dose-dependent increases in UBE3A protein expression (2 weeks) of a406 according to one embodiment of the present invention in human cerebral organoids. Figure 18a shows the results of Western blotting for UBE3A and GAPDH protein expression, and Figure 18b shows the fold change in the amount of UBE3A protein expression relative to GAPDH in the data of Figure 18a compared to the group not treated with ASO (0 μM).
[0153] Figures 19a and 19b show the dose-dependent effect of a748 according to one embodiment of the present invention on UBE3A splicing in human cerebral organoids (2 weeks). Figure 19a shows RT-PCR results, and Figure 19b shows UBE3A isoform-specific RT-qPCR results, where the expression levels of each UBE3A isoform relative to GAPDH mRNA are expressed as fold change compared to the condition without ASO treatment (Mock).
[0154] Figure 20 shows the results of analyzing the change in UBE3A mRNA isoform expression in cerebral organoids by a748, an ASO according to one specific example of the present invention, using RNA-seq.
[0155] Figures 21a, 21b, and 21c show the dose-dependent increasing effect (2 weeks) of a748 according to one embodiment of the present invention on UBE3A protein expression in human cerebral organoids. Figure 21a shows the results of Western blotting for UBE3A and GAPDH protein expression, and Figure 21b shows the fold change in UBE3A protein expression relative to GAPDH following a748 treatment compared to the condition without ASO treatment (0 μM). Figure 21c visually displays the change in UBE3A protein expression relative to GAPDH in the a748 treatment group based on the data of Figure 21b by integrating it into a bar graph.
[0156] Figure 22 shows the results of a toxicity evaluation of ASO according to one specific example of the present invention. Figure 22 shows the ASO and dosage for the control and experimental groups, and the survival rate 7 days after ASO administration ([number of surviving mice] / [total number of mice used in the ASO toxicity test]).
[0157] Figures 23a and 23b show the effect of ASO (a406, a748) according to one embodiment of the present invention on UBE3A protein expression in cerebral organoids derived from Angelman syndrome patients. Figure 23a shows the results of Western blotting for UBE3A and GAPDH protein expression, and Figure 23b shows the change in UBE3A protein expression relative to GAPDH in the ASO (a406, a748) treated group as a bar graph, expressed as a fold change relative to the group not treated with ASO (0 μM).
[0158] Figure 24 shows the results of an RNA-seq analysis of the change in the expression of UBE3A mRNA isoform in cerebral organoids derived from Angelman syndrome patients by a748, an ASO according to one specific example of the present invention.
[0159]
[0160] The present invention will be more clearly understood by reference to the following detailed embodiments, illustrated in the accompanying drawings. However, the present invention is not limited to these embodiments and may be implemented in various forms. These embodiments are provided solely to ensure complete disclosure of the present invention and to fully convey the scope of the invention to those skilled in the art. The present invention is defined by the claims.
[0161]
[0162] Example 1. Identification of a target region within the 5'-untranslated region of UBE3A.
[0163] 1.1. Identification of the target region within the UBE3A5' untranslated region through re-analysis of HEK293T polysome profiling data.
[0164] mRNAs present in HEK293T cells were separated according to the number of bound ribosomes (translation efficiency), and RNA-seq was performed on each fraction to analyze the polysome profile data (GEO accession number: GSE69352). The analysis results showed that isoforms with high translation efficiency were detected in large numbers in the fraction bound to a large number of ribosomes (high polysomes), whereas isoforms with low translation efficiency were mainly found in the fraction bound to a small number of ribosomes (low polysomes). From the polysome profile data, we identified a target region within the 5'untranslated region of the UBE3A gene (gene ID: 7337, RefSeq accession number: NM_130839.5) that significantly affects the translation activity of the UBE3A gene. The polysome profile data are shown in Figure 2. Polysome profiling data showed that splicing toward the inclusion of two exons (e1, e2) within the UBE3A5 untranslated region reduced translation efficiency, suggesting the presence of a translation repressor in this region. Furthermore, the data demonstrated a pattern of simultaneous inclusion and exclusion of both exons (e1, e2) within the UBE3A target region, suggesting that the presence of these two exons in mRNA may be correlated.
[0165]
[0166] 1.2. Identification of target regions within the UBE3A5 untranslated region through analysis of human neuronal polysome data.
[0167] To validate the data identified in HEK293T cells, target regions capable of inducing enhanced expression of UBE3A were identified using human neuronal polysome data.
[0168] RNA-seq was performed on each fraction, which was separated according to the number of ribosomes bound (translation efficiency) of mRNAs from human neuronal cells cultured for 50 days, and polysome profile data (GEO accession number: GSE100007) were analyzed. The analysis results showed that isoforms with high translation efficiency were mainly distributed in the fraction with many ribosomes bound (high polysomes), whereas isoforms with low translation efficiency were found more abundantly in the fraction with few ribosomes bound (low polysomes). The polysome profile data are shown in Figure 3. As in HEK293T cells, it was confirmed that the translation efficiency was reduced when two exons (e1, e2) within the 5' untranslated region of the UBE3A gene were included and spliced, indicating that they act as translation repressors in the translation of UBE3A.
[0169]
[0170] Furthermore, we quantified the relative expression levels of isoforms containing or not containing the target region within the UBE3A5'untranslated region in low and high polysomes from polysome profile data of human neuronal cells cultured for 50 days. To this end, we visualized the low and high polysome data using the Sashimi plot of the Integrative Genomics Viewer (IGV) browser and identified the number of junctions in the target region. Based on this, the number of splicing events that occurred in the region was calculated, and the relative expression ratio between isoforms containing and not containing the target region was calculated. The results are shown in Figure 4. When the number of ribosomes per mRNA was 2 to 4, it was classified as having low translation efficiency, and when the number of ribosomes was 5 or more, it was classified as having high translation efficiency. For Low polysomes with low translation efficiency, non-productive isoforms, i.e., isoforms containing exons e1 and / or e2, which were identified as translation repressors, were 1.8 times more abundant than productive isoforms not containing exons e1 and e2, whereas for High polysomes with high translation efficiency, productive isoforms were 1.9 times more abundant than non-productive isoforms. Consequently, we confirmed that UBE3A isoform forms that do not contain the target region of ASO were abundant in the High polysome fraction and relatively less abundant in the Low polysome fraction. These results indicate that exons e1 and / or e2 act as translation repressors when incorporated into mRNA by splicing.
[0171]
[0172] 1.3. Expression level of target region in brain tissue
[0173] Using the GTEx RNA-seq dataset, we examined the extent to which target regions within the UBE3A5' untranslated region are included in each human tissue after splicing. The results are shown in Figure 5. Compared to other tissues, brain tissue showed a higher abundance of mRNAs containing target regions within the UBE3A5' untranslated region.
[0174]
[0175] From polysome profile data, we confirmed that a translation repressor is contained within the 5' untranslated region of UBE3A, thereby affecting the translation activity of UBE3A. To enhance the translation activity of UBE3A, we developed a strategy to selectively exclude the corresponding region of UBE3A using an ASO targeting the translation repressor. A schematic diagram of the strategy is shown in Figure 6.
[0176]
[0177] Example 2. Design of antisense oligonucleotides (ASOs)
[0178] In order to induce enhanced expression of the UBE3A gene identified in Example 1, an ASO targeting the translational repression site present in the 5'-UTR of UBE3A pre-mRNA was designed.
[0179]
[0180] 2.1. Antisense oligonucleotide design
[0181] Twenty-one ASOs were designed around the e2 exon (196 nt, indicated by a rectangular box; SEQ ID NO: 99), one of the target exons. Figure 7 shows the locations of the ASOs designed to target the e2 exon and its surroundings. The target region, including the e2 exon and its surroundings, is indicated in the minus strand direction at hg38, chr15:25,407,025-25,407,296.
[0182] The target sequence of the designed ASO and the sequence information of the ASO sequence are shown in Table 1 below.
[0183]
[0184]
[0185] All nucleosides of the designed ASO used the 2'MOE modification, all internucleoside linkages were PS (phosphorothioate), and 5'-methyl-C bases were used instead of all C bases.
[0186]
[0187] To confirm the effect of the designed antisense oligonucleotide on splicing of UBE3A pre-mRNA, primers for RT-PCR were designed.
[0188] Forward (F) primer 5' - ACCCTGATGTCACCGAATGG (SEQ ID NO: 100)
[0189] Reverse (R) primer 5' - CGCTTCATTCGGCTAGCT (SEQ ID NO: 101)
[0190] The target site and primer sequences are shown in Figure 9.
[0191]
[0192] The relative expression levels of isoforms constituting the target region within the UBE3A5'untranslated region were confirmed by RT-PCR.
[0193]
[0194] 2.2. ASO screening by RT-PCR
[0195] The 21 designed candidate ASOs and 2 control ASOs (control ASO, AATGTTAGTGCTTGTTGAGGGC; NTC, TTAGTTTAATCACGCTCG) were injected into K562 cells using lipofectamine LTX at a final concentration of 200 nM, respectively. 24 hours after ASO injection, RNA was extracted and RT-PCR was performed to determine the relative changes in the expression levels of productive and non-productive isoforms of UBE3A induced by each candidate ASO. The results are shown in Figures 8a and 8b. Figure 8a shows the results of RT-PCR, and Figure 8b shows the ratio of non-productive isoforms compared to the Mock from the RT-PCR results. The Mock was treated only with lipofectamine LTX without injection of ASO. Among the 21 candidate ASOs, the ASOs that reduced the non-productive isoform compared to the control ASO treatment and mock treatment were a401, a403, a404, a405, a406, a407, a409, a411, a413, a414, a415, and a416, and the ASOs that reduced the non-productive isoform the most were a405 (SEQ ID NO: 33) and a406 (SEQ ID NO: 34).
[0196]
[0197] Example 3. ASO Optimization
[0198] 3.1. Optimization design
[0199] In the ASO screening of Example 2, 20 additional ASOs were designed around the target regions of a405 (SEQ ID NO: 33) and a406 (SEQ ID NO: 34), which showed the highest efficacy in reducing the non-productive isoform of UBE3A. Figure 10 shows a405 and a406 (unshaded arrow-shaped boxes) and the 20 additionally designed ASOs (shaded arrow-shaped boxes) aligned to the target exon e2, indicated by the rectangular box.
[0200] Table 2 below shows the target sequences and ASO sequences of ASOs designed around the target sites of ASOs selected for their ability to reduce the non-productive isoform of UBE3A.
[0201]
[0202]
[0203]
[0204] All nucleosides in the designed ASO used the 2'MOE modification, all internucleoside linkages were PS, and 5'-methyl-C bases were used instead of all C bases.
[0205]
[0206] 3.2. Optimization screening of ASOs used in RT-PCR
[0207] Twenty candidate ASOs derived through optimization design and one control ASO (Control ASO, AATGTTAGTGCTTGTTGAGGGC) were injected into K562 cells using lipofectamine LTX at a final concentration of 200 nM, and RT-PCR was performed with RNA extracted 24 hours after ASO injection to confirm the change in the relative expression levels of productive and non-productive isoforms of UBE3A caused by each candidate ASO. The results are shown in Figures 11a and 11b. Figure 11a shows the results of RT-PCR, and Figure 11b shows the ratio of non-productive isoforms compared to the Mock from the RT-PCR results. The Mock was treated only with lipofectamine LTX without injecting ASO. ASOs designed to optimize targeting around the target region of ASOs selected for their ability to reduce the non-productive isoform of UBE3A significantly reduced the non-productive isoform compared to both the control ASO and the mock, and a736, a740, a747, and a748 showed efficacy similar to a405 or better than a406.
[0208]
[0209] 3.3. Changes in UBE3A protein expression by ASO
[0210] The effect of ASO designed to target the region within the UBE3A 5'-UTR on UBE3A protein expression was confirmed in the K562 cell line.
[0211]
[0212] (1) Changes in UBSE3A protein expression level by ASO in K562 cell line
[0213] Candidate ASOs (a406, a736, a747, and a748) and a control ASO (a29) were injected into K562 cells using the electroporation method at a final concentration of 200 nM each, and the expression of UBE3A, b-actin, and GAPDH proteins was measured by Western blot analysis 48 hours after ASO injection. Antibodies against UBE3A, b-actin, and GAPDH were 10344-1-AP (Proteintech; 1:1000 dilution), A5316 (Sigma-Aldrich; 1:5000 dilution), and ab8245 (abcam; 1:5000 dilution), respectively. The results are shown in Figures 12a and 12b. Figure 12a shows the results of Western blot analysis, and Figure 12b shows the fold change relative to the condition (Mock) without ASO treatment after normalizing the UBE3A expression values for each condition in the data of Figure 12a to the b-actin and GAPDH expression values, respectively.
[0214] Candidate ASOs designed and screened against the target region of UBE3A increased UBE3A expression compared to the mock in K562 cells, with a406 showing the greatest increase.
[0215]
[0216] (2) Changes in UBE3A isoforms by a406 in K562 cell lines
[0217] We confirmed changes in UBE3A isoforms induced by a406 in K562 cells using RNA-seq. Specifically, a406 (the lead ASO) was injected into K562 cells at a final concentration of 200 nM using electroporation. RNA was extracted 24 hours after injection, and RNA-seq was performed. The results are shown in Figure 13. Compared to the condition without ASO injection (Mock), when a406 was injected, the expression of isoforms containing exons (e1, e2) of the target region was significantly reduced.
[0218]
[0219] Example 4. Effect of ASO on UBE3A expression in human cerebral organoids.
[0220] - Evaluation of brain-like models
[0221] To select a brain-like model to be used to evaluate the efficacy of ASO, the expression patterns of UBE3A isoforms in D160 cerebral organoids (derived from H9 Human Embryonic Stem Cells (hESC), Next&Bio), K562 cell lines, D40 human neuronal cells, and human brain tissues (whole brain tissue, human cerebral cortex tissue) were compared by RT-PCR. The results are shown in Fig. 14. In the case of K562 cell lines and D40 human neuronal cells, the proportion of non-productive isoforms was significantly lower than in brain tissue, making them unsuitable for evaluating the efficacy of ASO in brain tissue. Consequently, the cerebral organoid model was confirmed to best mimic the expression patterns of UBE3A isoforms in human brain tissue.
[0222] To evaluate the efficacy of ASO, cerebral organoids were selected as a brain-like model.
[0223]
[0224] - Information on primers and probes used in RT-qPCR
[0225] To confirm the UBE3A splicing effect of ASO targeting the 5'-UTR in UBE3A pre-mRNA by RT-qPCR analysis, primers and probes for each isoform were designed. The target regions and the primer sets and probes designed to detect UBE3A nonproductive isoform, UBE3A productive isoform, all UBE3A isoforms, and GAPDH are shown in Figure 15.
[0226]
[0227] 4.1. Dose-dependent effect of a406 on UBE3A splicing in human cerebral organoids.
[0228] Dose-dependent effects of a406 on UBE3A splicing alterations in human cerebral organoids (1 week)
[0229] D195 cerebral organoids were injected with a406 at the indicated doses (0, 10 μM, and 20 μM) based on the final concentration once every three days for one week via natural uptake (gymnosis). RT-PCR and RT-qPCR were performed. In RT-PCR, RNA extracted from each sample was reverse transcribed into cDNA, and the expression levels of isoforms within the target region were measured. In RT-qPCR, Taqman probe-based isoform-specific real-time quantitative PCR was performed using the same cDNA samples. This quantitatively analyzed the expression of each isoform. Figures 16a and 16b show the results of RT-PCR and RT-qPCR, respectively. Figure 16b shows the values of UBE3A mRNA relative to GAPDH mRNA under each condition and the fold change relative to the ASO-untreated condition. Error bars represent the 95% confidence intervals of the geometric means of the results of three biological replicates. RT-PCR confirmed that a406 treatment dose-dependently decreased the expression of nonproductive UBE3A isoforms and increased the expression of productive isoforms. Furthermore, isoform-specific RT-qPCR confirmed that nonproductive isoforms (including e1 and e2 exons) decreased in an a406 dose-dependent manner, while productive isoforms increased in an a406 dose-dependent manner, while total UBE3A mRNA levels remained unchanged. These results demonstrate that splicing was induced by ASO to increase the production of productive isoforms.
[0230]
[0231] Dose-dependent effects of a406 on UBE3A splicing alterations in human cerebral organoids (2 weeks)
[0232] As described above, a406 or control ASO (Control ASO, AATGTTAGTGCTTGTTGAGGGC) was injected into D195 brain organoids at the indicated doses (0, 10 μM, and 20 μM) based on the final concentration once every three days for two weeks by natural uptake, and then RT-PCR and RT-qPCR were performed. The results are shown in Figures 17a and 17b. Consistent with the results of the 1-week treatment, RT-PCR confirmed that a406 treatment dose-dependently decreased the expression of UBE3A nonproductive isoforms and increased the expression of productive isoforms, and isoform-specific RT-qPCR confirmed that nonproductive isoforms (including e1 and e2 exons) decreased in an a406 dose-dependent manner and productive isoforms increased in an a406 dose-dependent manner, while the total amount of UBE3A mRNA did not change.
[0233]
[0234] 4.2. Dose-dependent increase in UBE3A protein expression by a406 in human cerebral organoids (2 weeks)
[0235] The effect of a406 treatment on UBE3A protein expression was investigated in human cerebral organoids. D156 cerebral organoids were injected with a406 at the indicated final concentrations (0, 10 μM, 20 μM, 40 μM, and 80 μM) every three days for two weeks via natural uptake. Protein expression was then measured by capillary Western blotting (Jess Simple Western System) using antibodies against UBE3A and GAPDH, 10344-1-AP (Proteintech; 1:50 dilution) and ab8245 (abcam; 1:1500 dilution). The results are depicted in Figures 18a and 18b. A dose-dependent increase in UBE3A protein expression was observed following two weeks of a406 treatment.
[0236]
[0237] 4.3. Dose-dependent effects of a748 on UBE3A splicing in human cerebral organoids (2 weeks)
[0238] D170 cerebral organoids were injected with a748 at the indicated doses (0, 20 μM, 40 μM, and 80 μM) based on the final concentration once every three days for two weeks by natural uptake, and then RT-PCR and RT-qPCR were performed. The results are shown in Figures 19a and 19b. RT-PCR confirmed that the expression of non-productive isoforms of UBE3A decreased in a dose-dependent manner with a748 treatment, and isoform-specific RT-qPCR confirmed that the non-productive isoforms (including the e1 and e2 exons) decreased in an a748 dose-dependent manner, and the productive isoforms increased in an a748 dose-dependent manner.
[0239]
[0240] 4.4. Changes in UBE3A isoforms by a748 in human cerebral organoids
[0241] We confirmed changes in UBE3A isoforms induced by a748 in human cerebral organoids using RNA-seq. Specifically, a748 was injected into D170 cerebral organoids at a final concentration of 40 μM once every three days for two weeks via natural uptake, and RNA was extracted and subjected to RNA-seq. The results are shown in Figure 20. In human cerebral organoids, among the exons (e1, e2) of the target region, the form containing the e2 region was abundantly expressed, while the isoform containing the e1 region was barely expressed. Compared to the condition without ASO injection (Mock), the expression of the isoform containing the e2 region was significantly reduced under a748-treated condition.
[0242]
[0243] 4.5. Dose-dependent increase in UBE3A protein expression by a748 in human cerebral organoids (2 weeks)
[0244] The effect of a748 treatment on UBE3A protein expression was investigated in human cerebral organoids. D170 cerebral organoids were injected with a748 at the indicated final concentrations (0, 20 μM, 40 μM, and 80 μM) every three days for two weeks via natural uptake. Protein expression was then measured by capillary Western blotting (Jess Simple Western System) using antibodies against UBE3A and GAPDH, 10344-1-AP (Proteintech; 1:50 dilution) and ab8245 (abcam; 1:1500 dilution). The results are depicted in Figures 21a, 21b, and 21c. A dose-dependent increase in UBE3A protein expression was observed following two weeks of a748 treatment.
[0245]
[0246] Example 5. ASO toxicity evaluation
[0247] In vivo toxicity was evaluated by administering antisense oligonucleotides targeting the 5'-UTR of UBE3A pre-mRNA in mice.
[0248] Table 3 below shows the ASOs used for toxicity assessment.
[0249]
[0250]
[0251] All nucleosides in a28 and a30 used the 2'MOE variant, all internucleoside linkages were PS, and 5'-methyl-C bases were used instead of all C bases. a386, T*GCAG*5*8*7*8*5*7*7*7*8*8*TCTC*G; a639, A*GTAA*7*7*8*6*8*7*8*8*5*8*TCTCC (A=2'MOE-A, C=2'MOE-5'-methyl-C, G=2'MOE-G, T=2'MOE-T, 5=DNA-A, 6=DNA-5'-methyl-C, 7=DNA-G, 8=DNA-T, *=PS). a640, A*G*A*5*8*7*7*6*5*6*5*8*6*8*C*T*T*G (A=LNA-A, C=LNA-5'-methyl-C, G=LNA-G, T=LNA-T, 5=DNA-A, 6=DNA-C, 7=DNA-G, 8=DNA-T, *=PS).
[0252]
[0253] Toxicity evaluation of UBE3A candidate ASOs in postnatal day 2 (P2) mice
[0254] Two-day-old mice (species name: C57BL / 6N) were administered 2 μl of PBS (0 μg) or ASO (30 μg or 40 μg) via intracerebroventricular (ICV) injection into the left brain, and the survival was observed daily for 7 days to evaluate the toxicity of the administered ASO. The results are shown in Figure 22. Figure 22 shows the information on ASO administered to P2 mice and the survival rate 7 days after ASO administration calculated as [number of surviving mice] / [total number of mice used in ASO toxicity test].
[0255]
[0256] ASOs a406, a736, and a748, designed and screened to target the translational repression region in the 5'-UTR of UBE3A pre-mRNA, were found to have lower cytotoxicity compared to a386 and a28, which were included as toxicity controls.
[0257]
[0258] Example 6. Effect of ASO on UBE3A expression in cerebral organoids derived from Angelman syndrome patients.
[0259] 6.1. Effect of Lead ASO on Increased UBE3A Protein Expression in Organoids Derived from Angelman Syndrome Patients (Weeks 3 and 4)
[0260] The effects of treatment with lead ASOs (a406, a748) on UBE3A protein expression were investigated in organoids derived from Angelman syndrome patients. Specifically, induced pluripotent stem cells (iPSCs) derived from an Angelman syndrome patient (NM_130839.5(UBE3A):c.2289G>A) were differentiated into cerebral organoids and cultured for 120 days. Afterwards, a406 or a748 was injected at a final concentration of 40 μM every three days for three or four weeks via natural uptake. Subsequently, protein expression was measured by capillary Western blotting (Jess Simple Western System) using antibodies against UBE3A and GAPDH, 10344-1-AP (Proteintech; 1:50 dilution) and ab8245 (abcam; 1:1500 dilution). The results are shown in Figures 23a and 23b. In Figure 23a, each lane of the Western blot represents an independent biological replicate experiment. Figure 23b shows the data from Figure 23a as a bar graph quantifying the change in UBE3A protein expression relative to GAPDH in the lead ASO-treated group. It was confirmed that UBE3A protein expression increased approximately 1.2-fold in the lead ASO-treated group compared to the ASO-untreated group (Mock).
[0261]
[0262] 6.2. Changes in UBE3A isoforms by a748 in organoids derived from Angelman syndrome patients.
[0263] We confirmed changes in UBE3A isoforms induced by a748 in organoids derived from Angelman syndrome patients using RNA-seq. Specifically, induced pluripotent stem cells derived from an Angelman syndrome patient (NM_130839.5 (UBE3A): c.2289G>A) were differentiated into cerebral organoids and cultured for 157 days. Afterwards, a748 was injected at a final concentration of 60 μM every three days for two weeks via natural uptake. RNA was extracted and subjected to RNA-seq. The results are shown in Figure 24. Compared to the condition without ASO injection (Mock), the expression of isoforms containing exons (e1, e2) of the target region was significantly reduced in the a748-treated condition.
Claims
1. An antisense oligonucleotide targeting the pre-mRNA of the human UBE3A gene, The antisense oligonucleotide comprises 13 to 40 consecutive nucleotides and binds to the target site of UBE3A pre-mRNA through hybridization via at least 13 consecutive Watson-Crick base pairings A:T or G:C or wobble base pairings G:U, I:A, I:C or I:U, thereby increasing the expression of UBE3A. An antisense oligonucleotide wherein the target region comprises a sequence selected from the group consisting of SEQ ID NOs: 9 to 11 and 47 to 66.
2. An antisense oligonucleotide according to claim 1, wherein the target site comprises a sequence selected from the group consisting of SEQ ID NOs: 11, 51, 62, and 63.
3. An antisense oligonucleotide according to claim 1, wherein the target site comprises a sequence selected from the group consisting of SEQ ID NOs: 11 and 63.
4. An antisense oligonucleotide targeting the pre-mRNA of the human UBE3A gene, The antisense oligonucleotide comprises 13 to 40 consecutive nucleotides and binds to more than 80% of the nucleobases of the target sequence of UBE3A pre-mRNA through hybridization via Watson-Crick base pairing A:T or G:C or floating base pairing G:U, I:A, I:C or I:U, thereby increasing the expression of UBE3A. An antisense oligonucleotide wherein the target sequence is a sequence selected from the group consisting of SEQ ID NOs: 9 to 11 and 47 to 66.
5. In claim 4, the antisense oligonucleotide is an antisense oligonucleotide having a sequence selected from the group consisting of SEQ ID NOs: 11, 51, 62, and 63.
6. In claim 4, the antisense oligonucleotide is an antisense oligonucleotide having a sequence selected from the group consisting of SEQ ID NOs: 11 and 63.
7. In claim 1, the antisense oligonucleotide comprises at least one modification of a chemically modified sugar moiety, a chemically modified base, and a chemically modified internucleoside linkage, The chemically modified sugar moiety comprises at least one of a sugar moiety modified with 2'-O-methyl, 2'-methoxyethoxy, 2'-OAmethoxyethyl (2'-MOE), 2'-dimethylaminoethoxy, 2'-dimethylaminoethoxyethoxy, 2'-fluoro, 2'-acetamide, morpholino, LNA (locked nucleic acid), or c-ET (S-contrained-ethyl), The modified base comprises at least one of 5-methyl-cytosine, 5-fluorocytosine, and 2-aminopurine bases, An antisense oligonucleotide wherein the chemically modified internucleoside linkage comprises a phosphorothioate linkage.
8. An antisense oligonucleotide according to claim 7, wherein the antisense oligonucleotide is composed of a nucleoside having a 2'-MOE modification, wherein the internucleoside linkages are phosphorothioate, and all cytosine (C) bases are 5'-methyl-cytosine.
9. In claim 1, the antisense oligonucleotide has one of the structures of the following chemical formulas (I) to (IV): A*A*G*A*T*T*G*C*T*T*C*C*A*A*A*C*T*T*G*T Formula (I); A*T*T*G*C*T*T*C*C*A*A*A*C*T*T*G*T*A*T*C*T Formula (II); C*C*C*C*A*A*G*A*T*T*G*C*T*T*C*C*A*A*A*C Formula (III); and G*T*A*C*C*C*A*A*G*A*T*T*G*C*T*T*C*C Formula (IV); An antisense oligonucleotide wherein, among the formulas, A is 2'MOE-A, C is 2'MOE-5'-methyl-C, G is 2'MOE-G, T is 2'MOE-T, * is PS (phosphorothioate), and 2'MOE is 2'-O-methoxyethyl.
10. In claim 1, the antisense oligonucleotide has one of the structures of the following chemical formulas (I) and (IV): A*A*G*A*T*T*G*C*T*T*C*C*A*A*A*C*T*T*G*T Formula (I); and G*T*A*C*C*C*A*A*G*A*T*T*G*C*T*T*C*C Formula (IV); An antisense oligonucleotide wherein, among the formulas, A is 2'MOE-A, C is 2'MOE-5'-methyl-C, G is 2'MOE-G, T is 2'MOE-T, * is PS (phosphorothioate), and 2'MOE is 2'-O-methoxyethyl.
11. A pharmaceutical composition for treating a disease associated with an abnormal level or activity of UBE3A, comprising an antisense oligonucleotide according to any one of claims 1 to 10, wherein the disease is Angelman syndrome.
12. A pharmaceutical composition for treating a disease in which a therapeutic effect is confirmed through enhanced expression of UBE3A, comprising a virus that expresses the antisense oligonucleotide of any one of claims 1 to 10 in a cell, wherein the disease is Angelman syndrome.
13. A method for screening a gene having a translation repressor or translation promoter regulated through alternative splicing, A step of obtaining polysome profile data for human or animal cells, A step of analyzing the above polysome profile data to select translation promoting factors and / or translation repressing factors regulated through alternative splicing, The above selection step selects a region that increases the number of ribosomes bound to mRNA when present as a translation promoting factor, A method of selecting a site that reduces the number of ribosomes bound to mRNA when present as a translation repressor.
14. In claim 13, the step of obtaining polysome profile data for the human or animal cell comprises: A step of obtaining a lysate from a human or animal cell and fractionating the mRNA according to the number of ribosomes bound to the mRNA through a sucrose gradient, and comprising a step of performing RNA-seq on each fraction of the isolated mRNA to generate polysome profile data identifying the mRNA present in each fraction, or A method comprising the step of obtaining polysome profile data for a human or animal cell that has been previously performed.
15. A method according to claim 13, wherein the selected translation repressor or translation promoter is used as a target of an antisense oligonucleotide that induces splicing to regulate the expression level of a target gene.
16. A method according to claim 15, wherein an antisense oligonucleotide is designed to induce splicing to remove the translation repressor in order to increase the expression of the target gene.
17. A method according to claim 15, wherein an antisense oligonucleotide is designed to induce splicing to include the translation repressor in order to reduce the expression of the target gene.
18. A method according to claim 15, wherein an antisense oligonucleotide is designed to induce splicing to include the translation promoting factor in order to increase the expression of the target gene.
19. A method according to claim 15, wherein an antisense oligonucleotide is designed to induce splicing to exclude the translation promoting factor in order to reduce the expression of the target gene.
Citation Information
Patent Citations
Skin treatment prediction method and skin treatment prediction device
KR1020240115630A
Apparatus for controlling motor driven power steering apparatus and method thereof
KR1020250030160A
Anchor pin for placing concrete and fixing textile grid, and concrete structure reinforcing method using the same
KR102210426B1
KR20200094152A
KR20210144822A
